Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
SLS009 significantly improved survival in r/r AML patients, with a median overall survival of 8.8 months, surpassing historical benchmarks. The therapy showed a 67% objective response rate in AML-MRC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results